Molecular and physiological effects of muscle wasting and its treatment by blocking myostatin and activins
Julkaistu sarjassa
JYU dissertationsTekijät
Päivämäärä
2020Tekijänoikeudet
© The Author & University of Jyväskylä
Muscle wasting, occurring e.g. in cancer, is associated with poor prognosis, and cancer treatments may even exacerbate the wasting. The prevention of muscle wasting has improved survival in preclinical cancer models, but the mechanisms are poorly understood. The purpose of this dissertation was to study the molecular and physiological effects of different wasting conditions and their treatment by myostatin/activin blocking. The effects of myostatin/activin blocking were studied in (1) doxorubicin (DOX) chemotherapy-treated mice, (2) tumour-bearing (TB) mice, and (3) fasted and inactive mice. Myostatin/activin blocking prevented muscle wasting in DOX-treated and TB mice. In TB mice, this was associated with improved survival, but not when myostatin/activin blocking was used to increase muscle mass only before cancer. Myostatin/activin blocking also restored bone density in DOX-treated mice, but did not counteract the impaired running capacity and the decreased physical activity in DOX-treated and TB mice, respectively. Muscle protein synthesis was decreased by DOX and restored by myostatin/activin blocking in skeletal muscle, but not in the heart. The transcriptomic responses to DOX and myostatin/activin blocking were also larger in skeletal muscle than in the heart. Muscle protein synthesis was also decreased in TB mice. This was associated with reduced mTORC1 signalling and decreased colocalization of mTOR with lysosomes, which were restored by myostatin/activin blocking. Myostatin/activin blocking also induced muscle protein synthesis in healthy mice independent of alterations in physical activity and food intake and increased the amount of mTOR colocalised with lysosomes. This study shows that prevention of muscle wasting by myostatin/activin blocking improves survival in experimental cancer and has other beneficial effects beyond skeletal muscle in chemotherapy and cancer. In addition, maintaining muscle mass may be more beneficial in terms of survival than having a larger muscle mass before the cachectic stimulus. Finally, muscle protein synthesis and mTORC1 signalling induced by myostatin/activin blocking may be mediated via increased mTOR-lysosome colocalisation in healthy and cachectic muscles. This dissertation contributes to the cachexia research with novel results that may advance the development of strategies to prevent or treat cachexia.
...
Julkaisija
Jyväskylän yliopistoISBN
978-951-39-8468-7ISSN Hae Julkaisufoorumista
2489-9003Julkaisuun sisältyy osajulkaisuja
- Artikkeli I: Nissinen, T., Degerman, J., Räsänen, M., Poikonen, A. R., Koskinen, S., Mervaala, E., . . . Hulmi, J. (2016). Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Scientific Reports, 6, 32695. DOI: 10.1038/srep32695
- Artikkeli II: Hulmi, J., Nissinen, T., Räsänen, M., Degerman, J., Lautaoja, J., Hemanthakumar, K. A., . . . Kivelä, R. (2018). Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. Journal of Cachexia, Sarcopenia and Muscle, 9 (2), 417-432. DOI: 10.1002/jcsm.12265
- Artikkeli III: Nissinen, T., Hentilä, J., Penna, F., Lampinen, A., Lautaoja, J., Fachada, V., . . . Hulmi, J. (2018). Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. Journal of Cachexia, Sarcopenia and Muscle, 9 (3), 514-529. DOI: 10.1002/jcsm.12310
- Artikkeli IV: Nissinen, T.A., Hentilä, J., Fachada, V., Lautaoja, J.H., Pasternack, A., Ritvos, O., Kivelä, R. & Hulmi, J.J. Muscle Follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting. In revision.
Asiasanat
syöpätaudit molekyylit lääkehoito hiiret fyysinen aktiivisuus luuntiheys juoksu lihasmassa lihaskato kakeksia myostatiinit kemoterapia luurankolihakset proteiinisynteesi aktiviinit activin cancer cachexia chemotherapy muscle wasting myostatin physical activity protein synthesis skeletal muscle aktiviini myostatiini cancerous diseases muscles lihakset
Metadata
Näytä kaikki kuvailutiedotKokoelmat
- JYU Dissertations [846]
- Väitöskirjat [3563]
Lisenssi
Samankaltainen aineisto
Näytetään aineistoja, joilla on samankaltainen nimeke tai asiasanat.
-
Activin-A, myostatin and interleukin-6 in cancer associated cachexia
Härkönen, Jouni (2017)Cachexia is a muscle wasting condition associated with multiple different chronic illnesses, such as cancer, diabetes and AIDS. In cancer, approximately 80% of patients with advanced disease have symptoms of muscle wasting, ... -
Muscle follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting
Nissinen, Tuuli A.; Hentilä, Jaakko; Fachada, Vasco; Lautaoja, Juulia H.; Pasternack, Arja; Ritvos, Olli; Kivelä, Riikka; Hulmi, Juha J. (John Wiley & Sons, 2021)Blocking of myostatin and activins effectively counteracts muscle atrophy. However, the potential interaction with physical inactivity and fasting in the regulation of muscle protein synthesis is poorly understood. We used ... -
Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver
Hentilä, Jaakko; Nissinen, Tuuli; Korkmaz, Ayhan; Lensu, Sanna; Silvennoinen, Mika; Pasternack, Arja; Ritvos, Olli; Atalay, Mustafa; Hulmi, Juha (Frontiers Research Foundation, 2019)Muscle wasting in cancer cachexia can be alleviated by blocking activin receptor type 2 (ACVR2) ligands through changes in protein synthesis/degradation. These changes in cellular and protein metabolism may alter protein ... -
Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle
Hulmi, Juha; Nissinen, Tuuli; Räsänen, Markus; Degerman, Joni; Lautaoja, Juulia; Hemanthakumar, Karthik Amudhala; Backman, Janne T.; Ritvos, Olli; Silvennoinen, Mika; Kivelä, Riikka (Wiley, 2018)Background Toxicity of chemotherapy on skeletal muscles and the heart may significantly contribute to cancer cachexia, mortality, and decreased quality of life. Doxorubicin (DOX) is an effective cytostatic agent, which ... -
Exercise Medicine for Cancer Cachexia : Targeted Exercise to Counteract Mechanisms and Treatment Side Effects
Mavropalias, Georgios; Sim, Marc; Taaffe, Dennis, R.; Galvão, Daniel A.; Spry, Nigel; Kraemer, William, J.; Häkkinen, Keijo; Newton, Robert, U. (Springer Science and Business Media LLC, 2022)Purpose -- Cancer-induced muscle wasting (i.e., cancer cachexia, CC) is a common and devastating syndrome that results in the death of more than 1 in 5 patients. Although primarily a result of elevated inflammation, there ...
Ellei toisin mainittu, julkisesti saatavilla olevia JYX-metatietoja (poislukien tiivistelmät) saa vapaasti uudelleenkäyttää CC0-lisenssillä.